Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain.

Fanghui Shi, Huiyi Xia, Sharon Weissman, Xiaoming Li, Xueying Yang

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fanghui ShiSouth Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA. FSHI@email.sc.edu.ORCID http://orcid.org/0000-0002-5603-5398

Huiyi XiaSouth Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA.

Sharon WeissmanSouth Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA.

Xiaoming LiSouth Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA.

Xueying YangSouth Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daily oral pre-exposure prophylaxis (PrEP), including emtricitabine/tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide fumarate (TAF), is a key strategy for HIV prevention. Compared to TDF-based PrEP, TAF may be associated with greater weight gain. This study aims to examine the risk of weight gain among cisgender men and transgender women who were adults and took TAF for HIV prevention using real-world data. This study used data from All of Us, a nationwide research initiative designed to accelerate health and medical discoveries. All PrEP users in All of Us with at least two weight measures, one taken within 180 days prior to and the other between 90 and 365 days after initiating PrEP, were included in analyses. Linear regression was conducted to explore the association between different PrEP regimens and weight gain, adjusting for key sociodemographic characteristics. Among 385 eligible individuals, 284 were TDF-only users, 52 were TAF-only users, and 49 individuals switched from TDF to TAF. The median follow-up time for participants was 312 days. The average weight gain (in kilograms) for TDF-only, TAF-only, and TDF-TAD groups was - 0.68 (standard deviation [SD] = 5.43), 1.80 (SD = 11.60), and 1.74 (SD = 6.35), respectively. TAF-only (β = 2.532, 95%CI 0.708-4.356) and TDF-TAF (β = 2.756, 95%CI 0.890-4.621) were associated with significantly increased weight gain compared to TDF-only use. Closer monitoring of weight gain is recommended for individuals using TAF to prevent HIV.

Indexed as

AdenineAnti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisTenofovirWeight GainAdultAlanineFemaleHumansMaleMiddle AgedYoung AdultAdenineAlanineAnti-HIV AgentsTenofovirtenofovir alafenamidePre-exposure prophylaxisTenofovir alafenamide fumarateWeight gain

Identifiers

PMID41249192

DOI10.1038/s41598-025-23810-5

PMCPMC12623904

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.